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Abstract
Objective
To expand the clinical phenotype of POLR3A mutations by assessing the functional conse-
quences of a missense and a splicing acceptor mutation.
Methods
We performed whole-exome sequencing for identification of likely pathogenic mutations in a
9-year-old female patient with severe generalized dystonia, metabolic acidosis, leukocytosis,
hypotonia, and dysphagia. Brain MRI showed basal ganglia atrophy and presence of lactate and
lipid peaks by [1H]-magnetic resonance spectroscopy. Expression levels of Pol III target genes
were measured by quantitative real-time (qRT)-PCR to study the pathogenicity of the biallelic
mutations in patient fibroblasts.
Results
The patient is a compound heterozygous for a novel missense c.3721G>A (p.Val1241Met) and
the splicing region c.1771-6C>Gmutation in POLR3A, the gene coding for the catalytic subunit
of RNA polymerase III (Pol III). Aberrant splicing was observed for the c.1771-6C>G muta-
tion. Decreased RNA expression levels of Pol III targets (HNRNPH2, ubiquitin B, lacto-
transferrin, and HSP90AA1) were observed in patient fibroblasts with rescue to normal levels
by overexpression of the wild-type protein but not by the p.Val1241Met variant.
Conclusions
Mutations in the POLR3A gene cause POLR3A-related hypomyelinating leukodystrophy with
or without oligodontia or hypogonadotropic hypogonadism (HLD7, OMIM: 607694) and
neonatal progeroid syndrome (OMIM: 264090), both with high phenotypic variability. We
demonstrated the pathogenicity of c.1771-6C>G and c.3721G>A mutations causing an early-
onset disorder. The phenotype of our patient expands the clinical presentation of POLR3A-
related mutations and suggests a new classification that we propose designating as Neuro-
developmental Disorder with Regression, Abnormal Movements, and Increased Lactate.
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POLR3A encodes the catalytic subunit A of Pol III, which is
responsible for the constitutive transcription of transfer
ribonucleic acids, mitochondrial RNA–processing RNA, 5S,
H1, and noncoding RNAs (ncRNAs), and involved in trans-
lation of several mRNA.1,2 Because of its involvement in the
transcription of so many different RNAs, it is not surprising
that mutations in POLR3A can lead to a variety of phenotypes.
Two different conditions are associated with POLR3A mu-
tations: HLD7 (OMIM: 607694) and neonatal progeroid
syndrome (NPS, OMIM: 264090). HLD7 is an autosomal
recessive early-onset leukodystrophy3 presented by hypo-
myelination, hypogonadotropic hypogonadism, hypodontia,
spasticity, dystonia, and neurodevelopmental regression.1,4
Like HLD7, NPS is also an autosomal recessive early-onset
disorder presenting a wide range of phenotypes including
macrocephaly, progeroid appearance, triangular face, micro-
gnathia, nystagmus, hypodontia, muscle atrophy, hypertonia,
and agenesis of the corpus callosum.5
Here, we present the c.3721G>A and c.1771-6C>G muta-
tions in POLR3A, with features not described in HLD7 nor
NPS. We propose that these mutations extend the phenotype
of POLR3A deficiency and create a new classification of pa-
tients with features similar to those presented here.
Methods
Standard protocol approvals, registrations,
and patient consents
Informed consent was obtained according to the Ethical Stan-
dards Committee of UFPR (CAAE: 84773818.2.0000.0102).
Case report
The proband is a 9-year-old girl with a healthy mother who had
no other pregnancies and a father diagnosed with depression.
Gastroesophageal reflux and ineffective breast sucking were ob-
served just after birth. When aged 5 months, she was apathetic
and presented generalized dystonia. Four months later, she re-
fused food with no swallowing disorder. Proteinmalnutrition was
observed, and oral administration of hypercaloric diet was started
with ensuing of metabolic acidosis (lactate 4.88, reference:
0.63–2.44 mmol/L, normal pH and decreased HCO3 21.4 ref-
erence: 22–29 mEq/L). She could sit but neither crawl nor walk.
Brain MRI, muscle biopsy, and karyotype were normal at age
1 year. Improvement of weight gain and hydration was ach-
ieved by nasogastric tube feeding. Gastrostomy was per-
formed but showed dumping, requiring thickening of diet.
She presented with recurrent lung infections, milestone re-
gression, and was unable to talk at 2 years. Worsening of
dystonia and hypodontia was observed, with the absence of 2
baby teeth, but permanent dentition developed.
Another MRI was performed at age 4 years (data not shown)
with total brain volume reduction and alterations in striatal
bodies. Four years later, new MRI showed bilateral hyper-
intensity in T2 (figure 1A, a–d) and FLAIR (figure 1A, e–g),
atrophy of the caudate nucleus and putamen with compen-
satory enlargement of the lateral ventricles. Absent enhance-
ment on postcontrast images (figure 1A, h–i) and increase of
lipids/lactate on [1H]-magnetic resonance spectroscopy were
observed, but the noisy background could contribute to
possible artifactual peaks (figure 1A, j).
EEG showed slight diffuse disorganization in background
activity, reflecting a diffuse cerebral dysfunction, with no as-
sociation with specific pathologic features. No epileptiform
activity was observed.
Amino acid analysis in blood showed increased levels of threonine,
glycine, alanine, alpha-aminobutyric acid, valine, cystine, iso-
leucine, leucine, tyrosine, phenylalanine, and ornithine. Urine
amino acid analysis showed increased levels of 3-hydroxybutyric
and reduced levels of methylsuccinic, 3-methylglutaconic, and
3-hydroxy-3-methylglutaric. In addition, she presents leukocytosis
and persistent metabolic acidosis with increased lactate (8.5, ref-
erence: 0.6–2.2 mmol/L), decreased pH (7.12, reference: 7.32 to
7.43), and increased ammonia levels (47, reference: 11–32 μmol/
L). Currently, she presents hypotonia, dysphagia, low weight,
diffusemuscular hypotrophy, and severe generalized dystoniawith
worsening of the condition at night, but no triggers identified.
Anticholinergic, benzodiazepine, antidopaminergic, gabaergic, and
anticonvulsant medications were used to decrease dystonia, un-
successfully. Physical neurologic examination shows orofacial
dyskinesias, normal cranial circumference, and symmetry with
neither abnormalities of cranial nerves nor facial dysmorphism.
The patient is fully wheelchair dependent for ambulation.
Analysis of WES data
DNAwas extracted from blood (DNeasy Kit; Qiagen). Whole-
exome sequencing (WES) was prepared (Illumina® Nextera)
and run (HiSeq 2000). Human GRCh37 reference genome
and aGATK-based pipeline6 were used. Sanger sequencing was
performed by Source BioScience, United Kingdom.
Fibroblasts
Fibroblasts were derived from the patient’s skin biopsy and
grown (high-glucose Dulbecco's Modified Eagle Medium Glu-
tamax, sodium pyruvate, 10% fetal bovine serum, and penicillin/
Glossary
ncRNA = noncoding RNA;NPS = neonatal progeroid syndrome; qRT = quantitative real-time; SDS-PAGE = sodium dodecyl
sulfate-polyacrylamide gel electrophoresis; VUS = variant of uncertain significance; WES = whole-exome sequencing.
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streptomycin) at 37°C (5% CO2). Cell immortalization and
rescue experiments were performed by lentiviral transduction
(pLOX-Ttag-iresTK, Addgene #12246, pWPXLd-POLR3A-HA
“WT or V1241M”and “empty vector”).
For Western blot, cells were lysed (Tris-HCl 20 mM, NaCl
150mM,EDTA1mM,Triton-X-100 1%, glycerol 10%, andMgCl2
1.5 mM plus protease inhibitors), centrifuged, and supernatants
mixedwith loading buffer for sodiumdodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and immunoblotting. Protein
concentration was measured (DC protein assay; Bio-Rad).
qRT-PCR
RNA was extracted using the Invitrogen TRIzol kit. cDNA was
prepared with reverse transcriptase (Invitrogen). For POLR3A
mRNA processing, cDNA was amplified by PCR, separated by
agarose gel electrophoresis, gel extracted, and Sanger se-
quenced. qRT-PCR of target genes was performed in duplicate
with Life Technologies TaqMan Assays (Applied Biosystems):
ncRNA (HNRNPH2, Hs01395062_m1) and mRNAs: ubiq-
uitin B (UBB), lactotransferrin (LTF), and HSP90AA1.
Statistical analysis
The differences among groups were calculated with 95%
confidence intervals (p < 0.05) using the one-way analysis of
variance and Tukey multiple comparison test. All data are
presented as mean ± SD of the mean (SD) of 3 biological
independent experiments in duplicates.
Data availability
Data will be available upon request.
Results
WES detected 2 mutations in POLR3A, a missense c.3721G>A
(p.Val1241Met–rs886141646), inherited from themother, and
a splicing region c.1771-6C>G (rs115020338), from the father
(figure 1B–C). Sequencing of mtDNA (data not shown)
revealed the presence of MT-CYB (c.14831G>A); no other
rare variant of uncertain significance (VUS) was found.
The c.3721G>A mutation has a frequency of <0.0001
(TOPMed), and MutationTaster2 classifies it as possibly
Figure 1 Brain MRI and chromatograms of DNA sequence and alignment of POLR3A in several species
(A) Brain MRI of the proband showing hyperintense signal in T2 (blue arrows), volumetric reduction of the putamen and caudate nucleus (a and f).
Spectroscopy (j) shows peak of lactate and lipids. (B) Segregation of POLR3A mutations c.1771-6C>A from the father and c.3721G>A from the mother to the
proband (indicated by an arrow). (C) Chromatograms showing mutations c.1771-6C>A in heterozygosity in the father (I-1) and c.3721G>A (p.V1241M) in
heterozygosity in the mother (I-2) and the presence of both in the proband (II-1). (D) Alignment of 1,241 residue of the POLR3A, species were selected from
sequences obtained from a 4-iteration PSI-BlastP with default parameter research.
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pathogenic (score 0.99). The valine residue in the 1,241 po-
sition is highly conserved in metazoans with bilateral sym-
metry, except in some species, which present isoleucine
instead (figure 1D).
Electrophoresis from control and proband fibroblasts detec-
ted 2 transcripts of shorter length along with the canonical
full-length mRNA (figure 2A). The longest product corre-
sponded to the full-length mRNA, the one right below it
showed deletion of exon 14, whereas the smallest one dis-
played the combined deletion of both exons 13 + 14 (figure
2B). An accumulation of shorter compared with full-length
products was more evident in the patient cells.
We tested the dependency of the patient’s fibroblast phenotype
on defective POLR3Aby expressingHA-tagged POLR3A, either
wild type (PPOLR3A_WT_1 and PPOLR3A_WT_2) or mutant
(PPOLR3A_V1241M_1, PPOLR3A_V1241M_2, and PPOLR3A_V1241M_3),
using the empty vector (PEV) as a negative control. Compared
with the control (Ctrl), patient-derived cell lines (P and PEV)
displayed low levels of POLR3A, whereas overexpressing cell
lines presented higher levels of the protein, as also demonstrated
by anti-HA antibody immunovisualization (figure 3A).
A significant decrease in the levels of the HNRNPH2, UBB,
LTF, and HSP90AA1 was observed in the patient’s fibroblasts
compared with controls in all cases except for HSP90AA1
compared with one of the controls, C1 (figure 3B–E). As
expected, no significant difference was detected between P
cells and PEV. Furthermore, patient cells overexpressing the
wild-type protein recovered basal or higher levels of Pol III
target genes. This was not the case for patient cells over-
expressing the p.V1241M variant, as their levels were similar
to or even lower than both patient cell lines, P and PEV.
Discussion
Here, we present a case report of a compound heterozygous
for c.1771-6C>G and c.3721G>A mutations in POLR3A. The
patient presented clinical features associated with HLD7 and
NPS, but also metabolic acidosis, leukocytosis, lipid and lac-
tate peak.
Leukodystrophy, characterized by hypomyelination or de-
myelination,7 hypogonadotropic hypogonadism, and nystag-
mus were absent, suggesting that the diagnosis of HLD7 is not
appropriate. Features associated with NPS, but not with
HLD7, such as feeding difficulties, recurrent respiratory in-
fections, and hypotonia, were identified in our patient. Nev-
ertheless, classical features of NPS such as progeroid
appearance and malar hypoplasia were not present, and
Figure 2 POLR3A transcript visualization and sequencing from patient and control fibroblasts
(A) Agarose gel electrophoresis performed
from cDNA extracted and amplified by PCR
from control and proband (II-1) fibroblasts. (B)
Sequencing of the POLR3A gene fromwild-type
(WT) and proband fibroblast demonstrating
the deletion of exon 14 (e14del) and exons 13
+ 14 (e13 + 14del).
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Figure 3 Western blot analysis of POLR3A and RNA expression levels of POL III targets in patient fibroblasts
(A) SDS-PAGE for POLR3A, HA, and GAPDH in control (Ctrl) and proband (P) fibroblasts expressing empty vector (PEV), POLR3A-HA wild type (PPOLR3A_WT_1 and
PPOLR3A_WT_2), and POLR3A-HA mutant (PPOLR3A_V1241M_1, PPOLR3A_V1241M_2, and PPOLR3A_V1241M_3); qRT-PCR measurement in fibroblasts isolated RNA showing
levels of (B) HNRNPH2, (C) UBB, (D) LTF, and (E) HSP90AA1 normalized per GAPDH. (F) Intersection among the patient features (caudate nucleus atrophy,
dysphagia, dystonia, finger clubbing, hypodontia, hypotonia, lactate peak, leukocytosis, lipid peak, low weight, metabolic acidosis, milestone regression,
putamen atrophy, and recurrent respiratory infection) and symptomsdescribed forNPS (aged face, agenesis of the corpus callosum, apparentmacrocephaly,
ataxia, beak-shaped nose, blue sclerae, broad eyebrows, Chiari malformation, cryptorchidism, Dandy-Walker malformation, decreased subcutaneous fat,
deep-set eyes, dental delayed eruption, developmental delay, downslanting palpebral fissures, downturned corners of mouth, ectropion, endocrine ab-
normalities, entropion, failure to thrive, fat accumulation around the buttocks, dysphagia, frontal bossing, generalized lipoatrophy, gynecomastia, hydro-
cephalus, hypertelorism, hypertonia, hypodontia, hypoplasia of the facial bones, hypoplastic ilia, hypotonia, hypotrichosis, increased triglycerides, intention
tremor, intrauterine growth retardation, irregular metaphyseal endplates, joint contractures, lagophthalmos, large feet, large hands, long fingers, long thin
bones with enlarged metaphyseal endplates, long toes, lower eyelid covering part of the cornea, malar hypoplasia, mandibular hypoplasia, mental re-
tardation, micrognathia, muscle atrophy, nasal high-pitched voice, natal teeth, nystagmus, parietal bossing, partly unossified atlas at birth, persistent
fontanelles, pinched nose, pointed chin, poor postnatal growth, progeroid appearance, prominent abdomen, prominent forehead, prominent scalp veins,
pseudohydrocephalus, recurrent respiratory infections, scoliosis, short stature, small mouth, sparse eyebrows, sparse eyelashes, thin diaphyses, thin ribs,
thin translucent skin, thin upper vermilion, triangular face, trident configuration of acetabula, upslanting palpebral fissures, and widely open sutures); and
HLD7 (abnormal smooth pursuit, ataxia, bladder dysfunction, cerebellar atrophy, cerebellar signs, cognitive regression, cortical atrophy, decreased vibratory
andpositional sense, delayeddentition, dental delayed eruption, delayedpuberty, developmental delay, drooling, dysarthria, dysmetria, dysphagia, dystonia,
extensor plantar responses, hyperreflexia, hypodontia, hypogonadotropic, hypogonadism hypomyelination, leukodystrophy, motor regression, myopia,
nystagmus, oligodontia, optic atrophy, peripheral neuropathy, postural tremor, seizures, short stature, spasticity, thinning of the corpus callosum, upper
motor neuron signs, vertical gaze limitation, and white matter rarefaction).
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diagnosis of NPS may also be unsuitable. Hypodontia is the
only symptom shared between our patient and both described
syndromes, whereas dystonia is presented only in HLD7
(figure 3F).
The c.1771-6C>Gmutation is located 6 nucleotides upstream
exon 14 of POLR3A, resulting in the loss of this exon. It is
classified as a VUS (ClinVar), and it has been reported in a
family with HLD7, causing basal ganglia atrophy with no
hypomyelination.3
Loss of exon 14 has been linked to reduced expression of the
splicing factor HNRNPH2, responsible for the regulation of
pre-mRNA splicing.3 Expression levels of HNRNPH2 were
reduced in patient’s fibroblasts, and we showed that over-
expression of WT POLR3A, but not of the mutated
p.Val1241Met variant, rescued the expression of HNRNPH2.
Decreased expression of UBB, LTF, and HSP90AA1 has been
previously found in other patients carrying the c.1771-6C>G
mutation in POLR3A.3 All the mRNAs expression levels were
decreased in the patient cells, with rescue of their expression
levels when WT but not p.Val1241Met POLR3A was over-
expressed, demonstrating the pathogenicity of the c.3721G>A
mutation.
No other VUS with correlation between the patient’s phe-
notype and previously associated disease genes was identified
in the nuclear genome. In mtDNA, the mutation
m.14831G>A was found in a patient with Leber hereditary
optic neuropathy, but no functional studies were performed.9
This variant was recently classified as benign in ClinVar fol-
lowing the American College of Medical Genetics guide-
lines10 (evidence codes: BS1, BS2, and BP4).
The clinical phenotype of our patient resembles a combina-
tion of symptoms of 2 conditions associated with POLR3A
mutations and even mutations in genes coding for POL III
targets,8 highlighting the difficulty of a clinical diagnosis and
reinforcing the importance of a detailed clinical report com-
bined with molecular studies.
In conclusion, we suggest a new classification to patients
carrying mutations in POLR3A, with neither leukodystrophy
nor NPS features, which we propose designating as Neuro-
developmental Disorder with Regression, Abnormal Move-
ments, and Increased Lactate.
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